Guggenheim keeps Buy on Johnson & Johnson stock
Published on 10/13/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Guggenheim reiterated a Buy rating and USD 287.00 target ahead of Johnson & Johnson's third-quarter results.
- Second-quarter revenue reached USD 25.31 billion, up 6.6 percent year over year, while adjusted EPS was USD 2.90.
- Johnson & Johnson stock was trading at EUR 234.38 at Lang & Schwarz on October 13, 2026, minus 0.41 percent versus the October 12 Xetra close.
- The company was scheduled to report third-quarter results on October 13, 2026, with an Enterprise Business Review set for December 8, 2026.
Johnson & Johnson (US4781601046) was trading at EUR 234.38 at Lang & Schwarz on October 13, 2026 at 12:31 p.m. CEST, minus 0.41 percent versus the Xetra close of October 12, 2026 at EUR 235.35. Investing.com reported that Guggenheim reiterated a Buy rating and a USD 287.00 price target ahead of the company's third-quarter results.
Guggenheim keeps its USD 287 target
The rating update arrived as Johnson & Johnson prepared to report its third-quarter 2026 results. Guggenheim forecast third-quarter revenue of USD 25.49 billion versus consensus of USD 25.37 billion, while its earnings-per-share forecast was USD 2.49 versus consensus of USD 2.69, according to Investing.com.
RBC Capital recently raised its target from USD 287.00 to USD 290.00 and retained an Outperform rating, while Bank of America Securities lifted its target from USD 278.00 to USD 282.00 and kept a Hold rating, Markets Insider reported.
What is driving the earnings setup?
Johnson & Johnson entered the report with second-quarter 2026 revenue of USD 25.31 billion, up 6.6 percent year over year. Adjusted earnings per share reached USD 2.90 versus consensus of USD 2.84, while Innovative Medicine sales rose 7.8 percent operationally to USD 16.40 billion, according to TradingView.
Management raised full-year 2026 revenue guidance to a midpoint of USD 101.10 billion and adjusted earnings-per-share guidance to USD 11.60-11.75. The comparison matters because the company is balancing pharmaceutical growth against pressure from the loss of exclusivity for Stelara.
Three milestones shape the story
On July 29, 2026, Johnson & Johnson announced the completed acquisition of Firefly Bio and agreements with Sail Biomedicines, with the transactions expected to dilute full-year 2026 earnings per share by USD 0.64, according to Investing.com. On October 2, 2026, the company reported two-year ICOTYDE data from a Phase 3 study involving 684 patients, according to Trivano. On October 7, 2026, Guggenheim reiterated its Buy rating and USD 287.00 target.
Results and strategy dates
Johnson & Johnson was scheduled to report third-quarter 2026 results before the market opened on October 13, 2026, according to TradingView. The next strategic date was the Enterprise Business Review scheduled for December 8, 2026.
Stock stays below its yearly high
The EUR 234.38 Lang & Schwarz price sits within the EUR 158.56 to EUR 242.00 52-week range shown for the euro listing on October 13, 2026. The stock was EUR 7.62 below that high, a gap of 3.15 percent, while the market capitalization was EUR 575.6 billion.
The further course of trading is shown by the continuously updated real-time quote of Johnson & Johnson stock.
Johnson & Johnson market data
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 13, 2026, 12:31 p.m. CEST): EUR 234.38
- Change versus Xetra close: minus 0.41 percent
- Xetra close (October 12, 2026): EUR 235.35
- Market capitalization: EUR 575.6 billion (as of October 13, 2026)
- 52-week range: EUR 158.56-242.00 (as of October 13, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report S&P 500.
